We have published a paper with the results from the first AGILE trial using molnupiravir in The Lancet Infectious Diseases Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial – The Lancet Infectious Diseases.

We have also issued a press release which is now live on the AGILE website AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2 – The AGILE Clinical Trial Platform.